{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:45:51Z","timestamp":1780566351686,"version":"3.54.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41591-024-03346-3","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T10:02:31Z","timestamp":1731319351000},"page":"3426-3428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Moving toward response-adapted trials in oncology"],"prefix":"10.1038","volume":"30","author":[{"given":"Jose","family":"P\u00e9rez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Antonarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"3346_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03266-2","author":"K Khoury","year":"2024","unstructured":"Khoury, K. et al. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03266-2 (2024).","journal-title":"Nat. Med."},{"key":"3346_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03267-1","author":"RA Shatsky","year":"2024","unstructured":"Shatsky, R. A. et al. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03267-1 (2024).","journal-title":"Nat. Med."},{"key":"3346_CR3","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1200\/JCO.2011.39.2779","volume":"30","author":"LJ Esserman","year":"2012","unstructured":"Esserman, L. J. et al. J. Clin. Oncol. 30, 3242\u20133249 (2012).","journal-title":"J. Clin. Oncol."},{"key":"3346_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/clpt.2009.68","volume":"86","author":"A Barker","year":"2009","unstructured":"Barker, A. et al. Clin. Pharmacol. Ther. 86, 97\u2013100 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"key":"3346_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/1740774514525691","volume":"11","author":"KM Kidwell","year":"2014","unstructured":"Kidwell, K. M. Clin. Trials 11, 445\u2013456 (2014).","journal-title":"Clin. Trials"},{"key":"3346_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/cpt.1723","volume":"107","author":"H Schmidli","year":"2020","unstructured":"Schmidli, H. et al. Clin. Pharmacol. Ther. 107, 806\u2013816 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"3346_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-13-0239","volume":"20","author":"A Prat","year":"2014","unstructured":"Prat, A. et al. Clin. Cancer Res. 20, 511\u2013521 (2014).","journal-title":"Clin. Cancer Res."},{"key":"3346_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3346_CR9","doi-asserted-by":"publisher","first-page":"PO1-20-13","DOI":"10.1158\/1538-7445.SABCS23-PO1-20-13","volume":"84","author":"H McArthur","year":"2024","unstructured":"McArthur, H. et al. Cancer Res. 84, PO1-20-13 (2024). (Supp. 9).","journal-title":"Cancer Res."},{"key":"3346_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","volume":"403","author":"JM P\u00e9rez-Garc\u00eda","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda, J. M. et al. Lancet 403, 1649\u20131659 (2024).","journal-title":"Lancet"},{"key":"3346_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.2967\/jnumed.123.266384","volume":"65","author":"G Gebhart","year":"2024","unstructured":"Gebhart, G. et al. J. Nucl. Med. 65, 708\u2013713 (2024).","journal-title":"J. Nucl. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03346-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03346-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03346-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T13:07:19Z","timestamp":1734095239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03346-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3346"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03346-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"11 November 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.P.-G. reports consulting\/advisory role for Lilly, Roche, Eisai, Daiichi Sankyo, AstraZeneca, Seattle Genetics, Gilead and MSD; travel compensation from Roche; and employment at MEDSIR. G.A. reports honoraria from MEDSIR. M.G. has received support for attending meetings and\/or travel from AstraZeneca, Gilead Sciences, Roche and Pfizer and has received honoraria from AstraZeneca, Gilead Sciences and Pfizer. A.L.-C. reports receiving research support from Roche, Agendia, Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Gilead and Daiichi Sankyo; serving as a consultant\/advisor for Lilly, Roche, Pfizer and Novartis; participation in speakers\u2019 bureaus for Lilly, AstraZeneca and Merck Sharp & Dohme; travel support from Roche, Pfizer and AstraZeneca; and stock or other ownership of MEDSIR and Initia-Research. J.C. reports serving as a consultant\/advisor for Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, HiberCell, BioInvent, GEMoaB, Gilead, Menarini, Zymeworks, Reveal Genomics and Expres2ion Biotechnologies; receiving honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme and Daiichi Sankyo; research funding to the institution from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta\/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman\u2013La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma C and Queen Mary University of London; holding stock in MEDSIR, Nektar Pharmaceuticals and Leuko (relative); receiving travel and accommodation expenses from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, AstraZeneca and Gilead; and holding patents, including one for pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent (US 2019\/0338368 A1).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}